Literature DB >> 10575284

Recent advantages in cannabinoid research.

R Mechoulam1.   

Abstract

Although the active component of cannabis Delta9-THC was isolated by our group 35 years ago, until recently its mode of action remained obscure. In the last decade it was established that Delta9-THC acts through specific receptors - CB1 and CB2 - and mimics the physiological activity of endogenous cannabinoids of two types, the best known representatives being arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol (2-AG). THC is officially used against vomiting caused by cancer chemotherapy and for enhancing appetite, particularly in AIDS patients. Illegally, usually by smoking marijuana, it is used for ameliorating the symptoms of multiple sclerosis, against pain, and in a variety of other diseases. A synthetic cannabinoid, HU-211, is in advanced clinical tests against brain damage caused by closed head injury. It may prove to be valuable against stroke and other neurological diseases. Copyright 1999 S. Karger GmbH, Freiburg

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10575284     DOI: 10.1159/000057151

Source DB:  PubMed          Journal:  Forsch Komplementarmed        ISSN: 1021-7096


  5 in total

Review 1.  Therapeutic potential of cannabinoids in CNS disease.

Authors:  J Ludovic Croxford
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.

Authors:  T Bisogno; L Hanus; L De Petrocellis; S Tchilibon; D E Ponde; I Brandi; A S Moriello; J B Davis; R Mechoulam; V Di Marzo
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

3.  Overexpression of cannabinoid receptor 1 promotes renal cell carcinoma progression.

Authors:  Jianfeng Wang; Yunze Xu; Yun Zou; Liangsong Zhu; Baijun Dong; Jiwei Huang; Yonghui Chen; Wei Xue; Yiran Huang; Wen Kong; Jin Zhang
Journal:  Tumour Biol       Date:  2016-10-18

Review 4.  The endocannabinoid system in obesity and type 2 diabetes.

Authors:  V Di Marzo
Journal:  Diabetologia       Date:  2008-06-18       Impact factor: 10.122

5.  Biomarkers of endocannabinoid system activation in severe obesity.

Authors:  Jack C Sipe; T Michael Scott; Sarah Murray; Olivier Harismendy; Gabriel M Simon; Benjamin F Cravatt; Jill Waalen
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.